Page last updated: 2024-10-31

midazolam and Cancer of Pancreas

midazolam has been researched along with Cancer of Pancreas in 1 studies

Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Oshima, Y1
Sano, M1
Kajiwara, I1
Ichimaru, Y1
Itaya, T1
Kuramochi, T1
Hayashi, E1
Kim, J1
Kitajima, O1
Masugi, Y1
Masamune, A1
Ijichi, H1
Ishii, Y1
Suzuki, T1

Other Studies

1 other study available for midazolam and Cancer of Pancreas

ArticleYear
Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma.
    British journal of anaesthesia, 2022, Volume: 128, Issue:4

    Topics: Animals; Carcinoma, Pancreatic Ductal; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Midaz

2022